FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090105299> ?p ?o ?g. }

• W2090105299 endingPage "3162" @default.
• W2090105299 startingPage "3151" @default.
• W2090105299 abstract "Voltage-gated potassium channel complex antibodies, particularly those directed against leucine-rich glioma inactivated 1, are associated with a common form of limbic encephalitis that presents with cognitive impairment and seizures. Faciobrachial dystonic seizures have recently been reported as immunotherapy-responsive, brief, frequent events that often predate the cognitive impairment associated with this limbic encephalitis. However, these observations were made from a retrospective study without serial cognitive assessments. Here, we undertook the first prospective study of faciobrachial dystonic seizures with serial assessments of seizure frequencies, cognition and antibodies in 10 cases identified over 20 months. We hypothesized that (i) faciobrachial dystonic seizures would show a differential response to anti-epileptic drugs and immunotherapy; and that (ii) effective treatment of faciobrachial dystonic seizures would accelerate recovery and prevent the development of cognitive impairment. The 10 cases expand both the known age at onset (28 to 92 years, median 68) and clinical features, with events of longer duration, simultaneously bilateral events, prominent automatisms, sensory aura, and post-ictal fear and speech arrest. Ictal epileptiform electroencephalographic changes were present in three cases. All 10 cases were positive for voltage-gated potassium channel-complex antibodies (346-4515 pM): nine showed specificity for leucine-rich glioma inactivated 1. Seven cases had normal clinical magnetic resonance imaging, and the cerebrospinal fluid examination was unremarkable in all seven tested. Faciobrachial dystonic seizures were controlled more effectively with immunotherapy than anti-epileptic drugs (P = 0.006). Strikingly, in the nine cases who remained anti-epileptic drug refractory for a median of 30 days (range 11-200), the addition of corticosteroids was associated with cessation of faciobrachial dystonic seizures within 1 week in three and within 2 months in six cases. Voltage-gated potassium channel-complex antibodies persisted in the four cases with relapses of faciobrachial dystonic seizures during corticosteroid withdrawal. Time to recovery of baseline function was positively correlated with time to immunotherapy (r = 0.74; P = 0.03) but not time to anti-epileptic drug administration (r = 0.55; P = 0.10). Of 10 cases, the eight cases who received anti-epileptic drugs (n = 3) or no treatment (n = 5) all developed cognitive impairment. By contrast, the two who did not develop cognitive impairment received immunotherapy to treat their faciobrachial dystonic seizures (P = 0.02). In eight cases without clinical magnetic resonance imaging evidence of hippocampal signal change, cross-sectional volumetric magnetic resonance imaging post-recovery, after accounting for age and head size, revealed cases (n = 8) had smaller brain volumes than healthy controls (n = 13) (P < 0.001). In conclusion, faciobrachial dystonic seizures can be prospectively identified as a form of epilepsy with an expanding phenotype. Immunotherapy is associated with excellent control of the frequently anti-epileptic drug refractory seizures, hastens time to recovery, and may prevent the subsequent development of cognitive impairment observed in this study." @default.
• W2090105299 created "2016-06-24" @default.
• W2090105299 creator A5001210590 @default.
• W2090105299 creator A5011985314 @default.
• W2090105299 creator A5031467390 @default.
• W2090105299 creator A5031742616 @default.
• W2090105299 creator A5038094544 @default.
• W2090105299 creator A5044570092 @default.
• W2090105299 creator A5045615014 @default.
• W2090105299 creator A5045704773 @default.
• W2090105299 creator A5047360796 @default.
• W2090105299 creator A5057635638 @default.
• W2090105299 creator A5062939642 @default.
• W2090105299 creator A5066173178 @default.
• W2090105299 creator A5075599210 @default.
• W2090105299 creator A5077080413 @default.
• W2090105299 creator A5079514582 @default.
• W2090105299 creator A5082051712 @default.
• W2090105299 creator A5089737028 @default.
• W2090105299 date "2013-09-06" @default.
• W2090105299 modified "2023-10-12" @default.
• W2090105299 title "Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype" @default.
• W2090105299 cites W1963984288 @default.
• W2090105299 cites W1985489478 @default.
• W2090105299 cites W1988366576 @default.
• W2090105299 cites W1989308631 @default.
• W2090105299 cites W1996510251 @default.
• W2090105299 cites W2001711511 @default.
• W2090105299 cites W2001958718 @default.
• W2090105299 cites W2009074935 @default.
• W2090105299 cites W2010681077 @default.
• W2090105299 cites W2011209527 @default.
• W2090105299 cites W2013953370 @default.
• W2090105299 cites W2028332032 @default.
• W2090105299 cites W2032678192 @default.
• W2090105299 cites W2053984362 @default.
• W2090105299 cites W2073352417 @default.
• W2090105299 cites W2073877537 @default.
• W2090105299 cites W2076805831 @default.
• W2090105299 cites W2085856553 @default.
• W2090105299 cites W2087529205 @default.
• W2090105299 cites W2099917041 @default.
• W2090105299 cites W2100252544 @default.
• W2090105299 cites W2110026843 @default.
• W2090105299 cites W2110675016 @default.
• W2090105299 cites W2111059541 @default.
• W2090105299 cites W2117619518 @default.
• W2090105299 cites W2118067546 @default.
• W2090105299 cites W2118987707 @default.
• W2090105299 cites W2131625303 @default.
• W2090105299 cites W2134389315 @default.
• W2090105299 cites W2140152000 @default.
• W2090105299 cites W2145685957 @default.
• W2090105299 cites W2146199022 @default.
• W2090105299 cites W2154980585 @default.
• W2090105299 cites W2157848968 @default.
• W2090105299 cites W2161346432 @default.
• W2090105299 cites W2164489995 @default.
• W2090105299 cites W2165392739 @default.
• W2090105299 cites W2169403125 @default.
• W2090105299 cites W2170121713 @default.
• W2090105299 cites W2170247488 @default.
• W2090105299 doi "https://doi.org/10.1093/brain/awt212" @default.
• W2090105299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24014519" @default.
• W2090105299 hasPublicationYear "2013" @default.
• W2090105299 type Work @default.
• W2090105299 sameAs 2090105299 @default.
• W2090105299 citedByCount "331" @default.
• W2090105299 countsByYear W20901052992013 @default.
• W2090105299 countsByYear W20901052992014 @default.
• W2090105299 countsByYear W20901052992015 @default.
• W2090105299 countsByYear W20901052992016 @default.
• W2090105299 countsByYear W20901052992017 @default.
• W2090105299 countsByYear W20901052992018 @default.
• W2090105299 countsByYear W20901052992019 @default.
• W2090105299 countsByYear W20901052992020 @default.
• W2090105299 countsByYear W20901052992021 @default.
• W2090105299 countsByYear W20901052992022 @default.
• W2090105299 countsByYear W20901052992023 @default.
• W2090105299 crossrefType "journal-article" @default.
• W2090105299 hasAuthorship W2090105299A5001210590 @default.
• W2090105299 hasAuthorship W2090105299A5011985314 @default.
• W2090105299 hasAuthorship W2090105299A5031467390 @default.
• W2090105299 hasAuthorship W2090105299A5031742616 @default.
• W2090105299 hasAuthorship W2090105299A5038094544 @default.
• W2090105299 hasAuthorship W2090105299A5044570092 @default.
• W2090105299 hasAuthorship W2090105299A5045615014 @default.
• W2090105299 hasAuthorship W2090105299A5045704773 @default.
• W2090105299 hasAuthorship W2090105299A5047360796 @default.
• W2090105299 hasAuthorship W2090105299A5057635638 @default.
• W2090105299 hasAuthorship W2090105299A5062939642 @default.
• W2090105299 hasAuthorship W2090105299A5066173178 @default.
• W2090105299 hasAuthorship W2090105299A5075599210 @default.
• W2090105299 hasAuthorship W2090105299A5077080413 @default.
• W2090105299 hasAuthorship W2090105299A5079514582 @default.
• W2090105299 hasAuthorship W2090105299A5082051712 @default.
• W2090105299 hasAuthorship W2090105299A5089737028 @default.
• W2090105299 hasBestOaLocation W20901052991 @default.

• next